Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co., Inc.'s (NYSE:MRK) recent breakout above the $88 level took out both its 2021 and 2000 highs.

Why Call Traders Should Consider Merck Stock

European Commission approves Merck's (MRK) Keytruda as an adjuvant treatment for adults and adolescent patients with stage IIB or IIC melanoma and who have undergone complete resection.

Merck (MRK) Keytruda Gets Europe Nod for Expanded Melanoma Use

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA® Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

Seagen

Seagen had two setbacks this year - the below-consensus FY2022 guidance and the resignation of CEO Siegall. The stock shot up this month when rumors surfaced that Merck is interested in acquiring the company.

Seagen Would Be A Great Fit For Merck

Darden Restaurants

FedEx

J. M. Smucker

Do these dividend stocks have a place in your portfolio right now?

4 Top Dividend Stocks To Watch Amid Recession Concerns

AbbVie

Gilead Sciences

These stocks offer attractive dividends that investors should be able to count on.

3 Top Dividend Stocks for Generating Passive Income

McDonald's

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Investors can find safety from the bear market in these three Dow stocks. They offer low volatility, stable dividends and outperformance.

3 Dow Stocks to Buy for a Bear Market

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission Approves KEYTRUDA as Adjuvant Treatment for Adult & Adolescent Patients With Stage IIB or IIC Melanoma After Complete Resection

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection

Salesforce

NIKE

Investors seem to be adapting to the reality of a recession on the horizon.

3 Stocks That Drove the Dow's Nearly 200-Point Gain

Avnet

Cabot

First Commonwealth Financial

Raytheon Technologies

SPDR S&P 500 ETF Trust

These are 6 dividend income stocks with better yields than the S&P 500. These 6 stocks outperformed the S&P 500 this year and have higher yields, with earnings that can cover the dividends, making them good bets.

6 Dividend Income Stocks With Better Yields Than the S&P 500

Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Merck's (MRK) Pneumococcal Vaccine Gets FDA Nod for Kids

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CDC's ACIP Unanimously Votes to Provisionally Recommend Use of Merck's VAXNEUVANCE™ as an Option for Pneumococcal Vaccination in Infants and Children

CDC's ACIP Unanimously Votes to Provisionally Recommend Use of Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children

ANI Pharma

Could these pharmaceutical stocks be worth watching today?

What Stocks to Invest Today? 3 Pharmaceutical Stocks To Watch

General Mills

These stocks also make for fantastic long-term investments.

3 High-Yielding Dividend Stocks to Get You Through the Bear Market

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--US FDA Approves VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children

U.S. FDA Approves Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children

Chevron

UnitedHealth Group

Investors seemed to take a breather today after all of the selling last week.

3 Stocks That Drove the Dow's 641-Point Gain

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Results From Ph. 3 PROpel Trial of LYNPARZA® Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence

Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Chirfi Guindo will lead Human Health Marketing as chief marketing officer for Merck Human Health, and will join Merck's Executive Team, effective July 1, 2022. Guindo will report directly to Robert M. Davis, chief executive officer and president, Merck. As previously announced, Jannie Oosthuizen leads Merck Human Health U.S., and Joe Romanelli will lead Merck Human Health In

Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health

Coterra Energy

Growth-oriented investors may want to consider the following stocks, since they represent businesses with price-earnings ratios below 20 that recorded significant improvements in their trailing 12-month net earnings per share over the past year and are recommended by Wall Street analysts.

A Trio of Stocks for Growth-Oriented Investors

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company's Investigational Pneumococcal Conjugate Vaccine for Adults

Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company's Investigational Pneumococcal Conjugate Vaccine for Adults

Abbott Labs

Moderna

Check out these health care stocks this holiday-shortened week.

Best Health Care Stocks To Buy Now? 3 To Watch

Biopharma giant Merck is considering an acquisition of Seagen, the Seattle area's biggest biotech company, according to a report in the Wall Street Journal Friday.

Merck reportedly eyeing acquisition of Seattle biotech giant Seagen

Shares of Seagen Inc. ( SGEN , Financial) climbed more than 16% to about $170 on Friday as investors piled into the stock on rumors the company was being eyed by Merck & Co. Inc. ( MRK , Financial). A deal seems to make sense given the two pharmaceutical companies have been partners since 2020.

Seagen Shares Pop on Rumors of Merck Acquisition

Today, various reports have highlighted a potential deal for Merck to buy out Seagen, taking SGEN stock on a nice ride this afternoon. The post SGEN Stock Alert: Is Merck About to Buy Seagen?

SGEN Stock Alert: Is Merck About to Buy Seagen?

Merck & Co Inc (NYSE: MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28.

News for Merck Stock (MRK)